# Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB

> **NCT05063110** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 35 (actual)

## Conditions studied

- Adults Patients Having Non Severe HLH

## Interventions

- **DRUG:** Itacitinib

## Key facts

- **NCT ID:** NCT05063110
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-10-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063110, "Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05063110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*